Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Rapid Phenotype-Driven Gene Sequencing with the NeoSeq Panel: A Diagnostic Tool for Critically Ill Newborns with Suspected Genetic Disease

  • de Castro, M.J.
  • Gonzalez-Vioque, E.
  • Barbosa-Gouveia, S.
  • Salguero, E.
  • Rite, S.
  • Lopez-Suarez, O.
  • Perez-Munuzuri, A.
  • Couce, M.L.
New genomic sequencing techniques have shown considerable promise in the field of neonatology, increasing the diagnostic rate and reducing time to diagnosis. However, several obstacles have hindered the incorporation of this technology into routine clinical practice. We prospectively evaluated the diagnostic rate and diagnostic turnaround time achieved in newborns with suspected genetic diseases using a rapid phenotype-driven gene panel (NeoSeq) containing 1870 genes implicated in congenital malformations and neurological and metabolic disorders of early onset (<2 months of age). Of the 33 newborns recruited, a genomic diagnosis was established for 13 (39.4%) patients (median diagnostic turnaround time, 7.5 days), resulting in clinical management changes in 10 (76.9%) patients. An analysis of 12 previous prospective massive sequencing studies (whole genome (WGS), whole exome (WES), and clinical exome (CES) sequencing) in newborns admitted to neonatal intensive care units (NICUs) with suspected genetic disorders revealed a comparable median diagnostic rate (37.2%), but a higher median diagnostic turnaround time (22.3 days) than that obtained with NeoSeq. Our phenotype-driven gene panel, which is specific for genetic diseases in critically ill newborns is an affordable alternative to WGS and WES that offers comparable diagnostic efficacy, supporting its implementation as a first-tier genetic test in NICUs.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Two independent consecutive lymphoma cases carry an identical MYD88 mutation but differ in their IGVH rearrangement

  • Prieto-Torres, L
  • Trascasa, A
  • Manso, R
  • Machan, S
  • Cieza-Diaz, D
  • Olmedilla, G
  • Garcia-Garcia, M
  • Ara-Martin, M
  • Requena, L
  • Piris, MA
  • Rodriguez-Pinilla, SM
Several studies have provided evidence of the presence of lymphoma stem cells by showing the apparent transmission of premalignant lymphoid cells in allogeneic bone marrow transplantation, where the donor and recipient develop the same lymphoid disease.1-6 The lymphoid neoplasms do not develop at the same time, and in some cases, a different immunoglobulin heavy chain (IgH) rearrangement occurs in the two tumours. These data support the theory of a common lymphoma precursor cell (CPC) and make it less likely that it is due to a circulating donor tumour cell. Recently, Hattori et al.7 published genetic evidence of CPC in primary central nervous system diffuse large B-cell lymphoma (PCNS-DLBCL), suggesting that intra- and extra-CNS tumours in the same patient are derived from CPC with myeloid differentiation factor 88 (MYD88) L265P gene mutations, which arise before or after the IgH rearrangement. They suggested that CPC maps to different positions during B-lineage differentiation. The position after IgH rearrangement and even after hypermutation at the variable region could explain the appearance of clonally related lymphomas, whereas the emergence of CPC before IgH rearrangement might account for the presence of clonally unrelated B-cell lymphomas in the same patient because divergence may occur before the Variable-Diversity-Junctional (VDJ) rearrangements.